Treatment with Obecabtagene Autoleucel Results in Durable Response Among Adults with Relapsed or Refractory B-Cell ALL By Ogkologos - December 12, 2024 638 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the FELIX study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Teen Invents ‘Resilience Bra’ To Help Breast Cancer Patients With Post-Mastectomy... June 13, 2019 Studies Test CAR T-Cell Therapies Designed to Overcome Key Limitations February 8, 2023 Cancer Survivor And His Organ Donor Run NYC Marathon Together To... November 7, 2021 Lion With Skin Cancer Has Received Radiation Therapy In Hospital May 23, 2019 Load more HOT NEWS Pazopanib Is Not Inferior to Doxorubicin in First-Line Treatment of Elderly... Lack of Evidence for the Use of Telemedicine in the Prevention... Neoadjuvant Pertuzumab/Trastuzumab Demonstrates Long-Term Cardiac Safety in HER2-Positive Breast Cancer Preguntas frecuentes sobre el COVID-19 y el cáncer: Respuestas para pacientes...
